D&D Pharmatech reported final 48-week Phase 2 biopsy results for zabopegdutide, with 62.5% of treated patients achieving MASH resolution without worsening fibrosis compared with 5.3% on placebo. Half of treated patients showed fibrosis improvement without worsening of MASH, alongside reductions in liver enzymes, visceral adipose tissue, body weight and HbA1c. Fibrotic liver disease is a durable driver of metabolic and cardiovascular mortality, making regression of established scarring a meaningful endpoint.
Key Points
- 62.5% achieved MASH resolution versus 5.3% on placebo
- 50% showed fibrosis improvement without worsening of MASH
- Liver enzymes, visceral fat, weight and HbA1c declined
Longevity Analysis
Hepatic fibrosis represents accumulated damage at the body's primary filtration site, and its regression indicates that scarred tissue retains repair capacity when metabolic load is removed. The parallel reductions in visceral adipose tissue, circulating glucose markers and liver enzymes point to a single upstream driver rather than separate conditions, which reframes the liver as a readout of systemic metabolic burden. Digital pathology and non-invasive markers such as MRE, ELF and PRO-C3 offer a path to tracking structural liver change without serial biopsy — a practical shift for long-term monitoring.
Original published by LT Wire.